BRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million

Reuters

2025/02/25

Feb 25 (Reuters) - Elanco Animal Health Q4 adjusted EBITDA USD 177 million vs. IBES estimate USD 179.7 million.

Q4 adjusted net income USD 72 million vs. IBES estimate USD 74.9 million
outlook FY revenue USD 4,445-4,510 million
outlook FY adjusted EPS USD 0.8-0.86
outlook FY net income USD -25 to 7 million
outlook FY adjusted EBITDA USD 830-870 million

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514214098"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514214098\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514214098?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514214098","market":"us","top_or_hot":-1,"title":"BRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million</title>\n</head>\n<body>\n<p>Feb 25 (Reuters) - Elanco Animal Health Q4 adjusted EBITDA USD 177 million vs. IBES estimate USD 179.7 million.</p>\n<ul>\n<li>Q4 adjusted net income USD 72 million vs. IBES estimate USD 74.9 million</li>\n<li>outlook FY revenue USD 4,445-4,510 million</li>\n<li>outlook FY adjusted EPS USD 0.8-0.86</li>\n<li>outlook FY net income USD -25 to 7 million</li>\n<li>outlook FY adjusted EBITDA USD 830-870 million</li>\n</ul>\n</body>\n</html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-25 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million</title>\n</head>\n<body>\n<p>Feb 25 (Reuters) - Elanco Animal Health Q4 adjusted EBITDA USD 177 million vs. IBES estimate USD 179.7 million.</p>\n<ul>\n<li>Q4 adjusted net income USD 72 million vs. IBES estimate USD 74.9 million</li>\n<li>outlook FY revenue USD 4,445-4,510 million</li>\n<li>outlook FY adjusted EPS USD 0.8-0.86</li>\n<li>outlook FY net income USD -25 to 7 million</li>\n<li>outlook FY adjusted EBITDA USD 830-870 million</li>\n</ul>\n</body>\n</html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELAN","symbol_name":"Elanco Animal Health Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nPLX4705C0:1","article_id":"2514214098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514214098","pubTimestamp":1740485152,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Feb 25  - Elanco Animal Health Q4 adjusted EBITDA USD 177 million vs. IBES estimate USD 179.7 million.Q4 adjusted net income USD 72 million vs. IBES estimate USD 74.9 million","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ELAN":"Elanco Animal Health Inc"},"translate_title":"简介-Elanco Animal Health第四季度收入为10.2亿美元，而IBES预估为10.1亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAN":0.9},"content_text":"BRIEF-Elanco Animal Health Q4 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,010 Million\n\n\nFeb 25 (Reuters) - Elanco Animal Health Q4 adjusted EBITDA USD 177 million vs. IBES estimate USD 179.7 million.\n\nQ4 adjusted net income USD 72 million vs. IBES estimate USD 74.9 million\noutlook FY revenue USD 4,445-4,510 million\noutlook FY adjusted EPS USD 0.8-0.86\noutlook FY net income USD -25 to 7 million\noutlook FY adjusted EBITDA USD 830-870 million","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}